OBJECTIVES: Different immune alterations have been described in HIV-infected patients with visceral leishmaniasis (VL). We aimed to identify the immunological factors involved in the lack of immunological recovery and VL relapses in HIV-infected patients with VL, by comparison with other HIV-infected patients. METHODS: We carried out a cross-sectional study of 55 patients receiving suppressive combination antiretroviral therapy (cART) for at least 1 year: nine with previous relapsing VL, 20 with an immunodiscordant response (IDR) to cART (CD4 count < 200 cells/μL) and no previous VL, and 26 with a concordant response (CR) to cART (CD4 count > 350 cells/μL) without VL. Immunosenescence was investigated by analysing CD57(+) CD28(-) levels, immune activation by analysing CD38(+) HLA-DR(+) levels, inflammation by analysing interleukin (IL)-6 levels, and microbial translocation by analysing lipopolysaccharide (LPS) and soluble CD14 (sCD14) levels. RESULTS: In VL patients, the median time since VL diagnosis was 42 months, and all patients had had at least one relapse despite suppressive cART for a median time of 43 months. Patients with previously diagnosed VL had a higher CD8 T-cell activation level (P < 0.001) than those with IDR. Also, levels of IL-6, LPS and especially sCD14, associated with bacterial translocation and additional monocyte activation, were significantly increased in patients with previous VL compared with patients with IDR (P = 0.048, P = 0.049 and P < 0.001, respectively). In addition, patients with previous VL had higher levels of CD8 T-cell senescence. Notably, the levels of immune activation and inflammation in patients with previous VL were not related to the time of VL diagnosis, the number of VL relapses, or hepatitis C virus (HCV) coinfection. CONCLUSIONS: Our data demonstrate that VL patients had an even worse immunological status than patients with IDR, which was probably associated with increased microbial translocation and additional monocyte/macrophage activation. These data explain the observed lack of immunological recovery and the occurrence of VL relapses in HIV-infected patients with previous VL.
OBJECTIVES: Different immune alterations have been described in HIV-infectedpatients with visceral leishmaniasis (VL). We aimed to identify the immunological factors involved in the lack of immunological recovery and VL relapses in HIV-infectedpatients with VL, by comparison with other HIV-infectedpatients. METHODS: We carried out a cross-sectional study of 55 patients receiving suppressive combination antiretroviral therapy (cART) for at least 1 year: nine with previous relapsing VL, 20 with an immunodiscordant response (IDR) to cART (CD4 count < 200 cells/μL) and no previous VL, and 26 with a concordant response (CR) to cART (CD4 count > 350 cells/μL) without VL. Immunosenescence was investigated by analysing CD57(+) CD28(-) levels, immune activation by analysing CD38(+) HLA-DR(+) levels, inflammation by analysing interleukin (IL)-6 levels, and microbial translocation by analysing lipopolysaccharide (LPS) and soluble CD14 (sCD14) levels. RESULTS: In VL patients, the median time since VL diagnosis was 42 months, and all patients had had at least one relapse despite suppressive cART for a median time of 43 months. Patients with previously diagnosed VL had a higher CD8 T-cell activation level (P < 0.001) than those with IDR. Also, levels of IL-6, LPS and especially sCD14, associated with bacterial translocation and additional monocyte activation, were significantly increased in patients with previous VL compared with patients with IDR (P = 0.048, P = 0.049 and P < 0.001, respectively). In addition, patients with previous VL had higher levels of CD8 T-cell senescence. Notably, the levels of immune activation and inflammation in patients with previous VL were not related to the time of VL diagnosis, the number of VL relapses, or hepatitis C virus (HCV) coinfection. CONCLUSIONS: Our data demonstrate that VL patients had an even worse immunological status than patients with IDR, which was probably associated with increased microbial translocation and additional monocyte/macrophage activation. These data explain the observed lack of immunological recovery and the occurrence of VL relapses in HIV-infectedpatients with previous VL.
Authors: Diego Lins Guedes; Zulma Medeiros; Elis Dionísio da Silva; Audrey Violeta Martins de Vasconcelos; Mariana Santana da Silva; Maria Almerice Lopes da Silva; Paulo Sérgio Ramos de Araújo; Demócrito de Barros Miranda-Filho Journal: Am J Trop Med Hyg Date: 2018-12 Impact factor: 2.345
Authors: Tanya L Kowalczyk Mullins; Su X Li; James Bethel; Maureen M Goodenow; Stephanie Hudey; John W Sleasman Journal: J Clin Virol Date: 2018-02-07 Impact factor: 3.168
Authors: Angelita F Druzian; Albert S de Souza; Diogo N de Campos; Julio Croda; Minoru G Higa; Maria Elizabeth C Dorval; Mauricio A Pompilio; Polliana A de Oliveira; Anamaria M M Paniago Journal: PLoS Negl Trop Dis Date: 2015-08-14
Authors: Maria Luciana Silva-Freitas; Glaucia Fernandes Cota; Talia S Machado-de-Assis; Carmem Giacoia-Gripp; Ana Rabello; Alda M Da-Cruz; Joanna R Santos-Oliveira Journal: PLoS One Date: 2016-12-01 Impact factor: 3.240
Authors: José Angelo Lauletta Lindoso; Carlos Henrique Valente Moreira; Mirella Alves Cunha; Igor Thiago Queiroz Journal: HIV AIDS (Auckl) Date: 2018-10-15
Authors: Shauna McQuarrie; Ken Kasper; Dana C Moffatt; Daniel Marko; Yoav Keynan Journal: Can J Infect Dis Med Microbiol Date: 2015 Nov-Dec Impact factor: 2.471
Authors: Wim Adriaensen; Thomas P C Dorlo; Guido Vanham; Luc Kestens; Paul M Kaye; Johan van Griensven Journal: Front Immunol Date: 2018-01-12 Impact factor: 7.561
Authors: Felicity C Fitzgerald; Edouard Lhomme; Kathryn Harris; Julia Kenny; Ronan Doyle; Cissy Kityo; Liam P Shaw; George Abongomera; Victor Musiime; Adrian Cook; Julianne R Brown; Anthony Brooks; Ellen Owen-Powell; Diana M Gibb; Andrew J Prendergast; A Sarah Walker; Rodolphe Thiebaut; Nigel Klein Journal: J Infect Dis Date: 2019-01-01 Impact factor: 5.226